Goal Achievement after Utilizing an anti-PCSK9 antibody in Statin Intolerant Subjects-3GAUSS-3
Study Details
The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab administered subcutaneously (SC) every month, compared with ezetimibe, on low-density lipoprotein cholesterol (LDL-C) levels in adults with high cholesterol who are unable to tolerate an effective dose of a statin due to muscle-related side effects (MRSE).
Protocol Summary
Mean percent change from baseline in low density lipoprotein-cholesterol
Timeframe: 22 and 24 Weeks
Percent change from baseline in low density lipoprotein-cholesterol
Timeframe: 24 Weeks
Mean change from baseline in low density lipoprotein-cholesterol
Timeframe: 22 and 24 Weeks
Change from baseline in low density lipoprotein-cholesterol
Timeframe: 24 Weeks
Mean low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol < 70 mg/dL [1.8 mmol/L])
Timeframe: 22 and 24 Weeks
Low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol < 70 mg/dL [1.8 mmol/L])
Timeframe: 24 Weeks
Mean percent change from baseline in total cholesterol
Timeframe: 22 and 24 Weeks
Percent change from baseline in total cholesterol
Timeframe: 24 Weeks
Mean percent change from baseline in non-high density lipoprotein-cholesterol
Timeframe: 22 and 24 Weeks
Percent change from baseline in non-high density lipoprotein-cholesterol
Timeframe: 24 Weeks
Mean percent change from baseline in apolipoprotein B
Timeframe: 22 and 24 Weeks
Percent change from baseline in apolipoprotein B
Timeframe: 24 Weeks
Mean percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio
Timeframe: 22 and 24 Weeks
Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio
Timeframe: 24 Weeks
Mean percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio
Timeframe: 22 and 24 Weeks
Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio
Timeframe: 24 Weeks
Mean percent change from baseline in lipoprotein (a)
Timeframe: 22 and 24 Weeks
Percent change from baseline in lipoprotein (a)
Timeframe: 24 Weeks
Mean percent change from baseline in triglycerides
Timeframe: 22 and 24 Weeks
Percent change from baseline in triglycerides
Timeframe: 24 Weeks
Mean percent change from baseline in high density lipoprotein-cholesterol
Timeframe: 22 and 24 Weeks
Percent change from baseline in high density lipoprotein-cholesterol
Timeframe: 24 Weeks
Mean percent change from baseline in very low density lipoprotein-cholesterol
Timeframe: 22 and 24 Weeks
Percent change from baseline in very low density lipoprotein-cholesterol
Timeframe: 24 Weeks